Advancing
drug development
initiatives with contract research
and consulting services
Pascal Biosciences (TSXV:PAS; OTC:PSCBF; FSE:6PB-FF) is dedicated to improving the lives of patients suffering from life-threatening diseases. We have internal programs, and we provide contract research and consulting services to clients with their own drug development initiatives. Our value prospect is to use our in-house facilities and expertise to provide a cost effective development platform that enables the efficient evolution of client programs relieving them of the need to build and staff their own lab facilities.
Our expertise is concentrated on specific disease related drug development for oncology, immunology, neuroscience, and critical care.
Cannabinoid for COVID-19
In a cell-based assay, Pascal has identified a cannabinoid that blocks SARS-CoV-2 with a potency similar to remdesivir.
PAS-403 for Glioblastoma
PAS-403 is a cannabinoid-based small molecule that utilizes a unique mechanism of action to kill cancer cells. Clinical trials are targeted to begin in 2021.
PAS-393 for Cancer
PAS-393 is a cannabinoid that makes cancers visible to the immune system.
